

## Special Issue

# Research on Targeted Drugs in Cancer

### Message from the Guest Editors

Over the past two decades, the emergence of targeted therapies has transformed the therapeutic landscape for cancer treatment. Unlike conventional chemotherapies, which indiscriminately destroy both malignant and non-malignant cells, targeted therapies are designed to act specifically on cancer cells harboring particular mutations. This revolutionary precision medicine approach has resulted in effective tumor regression with reduced off-target toxicity. Targeted therapies now feature prominently in oncology clinical practice guidelines, and next-generation sequencing to identify actionable mutations has become part of the standard-of-care practice for multiple cancers. Despite this extraordinary progress, resistance to targeted cancer therapies remains a challenge, and continued research to define strategies for preventing and overcoming resistance is warranted. For this Special Issue of *Cancers*, we are interested in original research and review articles covering a broad range of topics related to targeted therapies, including (but not limited to) novel targets, clinical and regulatory aspects of development, and investigation into drug resistance mechanisms and management.

---

### Guest Editors

Dr. Marjorie E. Zettler

Clinical Science, Accutar Biotechnology Inc., Cranbury, NJ, USA

Dr. Bertal Aktas

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

---

### Deadline for manuscript submissions

closed (25 July 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/183202](https://mdpi.com/si/183202)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)